Summary

• Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption.
• Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years.
• CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026.
• Strong balance sheet with $1.65B net cash and disciplined R&D spending provides a 5–6 year runway, minimizing near-term CRSP dilution or capital risk.

Shares of Crispr Therapeutics AG (CRSP), the Zug, Switzerland-based biotechnology company, have been stuck within a trading range for about four and a half years now. Investor enthusiasm around the Casgevy launch – a one-time

1.12K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRSP, VRTX, NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.